Literature DB >> 890632

Early diagnosis of salt-losing congenital adrenal hyperplasia in a newborn boy.

I A Hughes, J S Winter.   

Abstract

Assays of serum 17-hydroxyprogesterone concentration may be relied upon to establish a diagnosis of congenital adrenal hyperplasia within a few hours of birth. In a male infant the concentration of 17-hydroxyprogesterone was increased in cord serum and remained elevated until glucocorticoid therapy was started on the 5th day of life. Plasma renin activity was increased only slightly in the first few days, but a striking increase on day 5, along with a gradual increase in the serum potassium concentration, confirmed that the infant had the salt-losing form of congenital adrenal hyperplasia. It was not possible to demonstrate an increased concentration of 17-hydroxyprogesterone, in amniotic fluid obtained at 30 weeks' gestation, presumably because of interference in this assay by cross-reacting steroids. Studies of the mother's serum concentration of 17-hydroxyprogesterone and cortisol during delivery did not disclose any deviation from normal.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 890632      PMCID: PMC1879750     

Source DB:  PubMed          Journal:  Can Med Assoc J        ISSN: 0008-4409            Impact factor:   8.262


  15 in total

1.  Evidence for partial 21-hydroxylase deficiency among heterozygote carriers of congenital adrenal hyperplasia.

Authors:  P A Lee; J F Gareis
Journal:  J Clin Endocrinol Metab       Date:  1975-08       Impact factor: 5.958

2.  Early diagnosis of congenital adrenal hyperplasia by measurement of 17-hydroxyprogesterone.

Authors:  E Youssefnejadian; R David
Journal:  Clin Endocrinol (Oxf)       Date:  1975-07       Impact factor: 3.478

3.  A study of the renin-angiotensin system in newborn infants.

Authors:  T A Kotchen; A L Strickland; T W Rice; D R Walters
Journal:  J Pediatr       Date:  1972-06       Impact factor: 4.406

4.  Application of a radioimmunoassay for angiotensin I to the physiologic measurements of plasma renin activity in normal human subjects.

Authors:  E Haber; T Koerner; L B Page; B Kliman; A Purnode
Journal:  J Clin Endocrinol Metab       Date:  1969-10       Impact factor: 5.958

5.  Sources of plasma 17alpha-hydroxyprogesterone in human pregnancy.

Authors:  D Tulchinsky; H H Simmer
Journal:  J Clin Endocrinol Metab       Date:  1972-12       Impact factor: 5.958

6.  Difficulties in the diagnosis of the adrenogenital syndrome in infancy.

Authors:  C H Shackleton; F L Mitchell; J W Farquhar
Journal:  Pediatrics       Date:  1972-02       Impact factor: 7.124

7.  Prenatal diagnosis of adrenogenital syndrome by amniocentesis.

Authors:  I R Merkatz; M I New; R E Peterson; M P Seaman
Journal:  J Pediatr       Date:  1969-12       Impact factor: 4.406

8.  Gas chromatographic estimation of urinary delta-5-pregnene-3-beta, 17-alpha, 20-alpha-triol.

Authors:  K Kinoshita; K Isurugi; Y Matsumoto; H Takayasu
Journal:  Steroids       Date:  1968-01       Impact factor: 2.668

9.  Plasma renin activity and aldosterone concentration in the human newborn.

Authors:  M J Dillon; M E Gillin; J M Ryness; M de Swiet
Journal:  Arch Dis Child       Date:  1976-07       Impact factor: 3.791

10.  The application of a serum 17OH-progesterone radioimmunoassay to the diagnosis and management of congenital adrenal hyperplasia.

Authors:  I A Hughes; J S Winter
Journal:  J Pediatr       Date:  1976-05       Impact factor: 4.406

View more
  3 in total

Review 1.  Management of congenital adrenal hyperplasia.

Authors:  I A Hughes
Journal:  Arch Dis Child       Date:  1988-11       Impact factor: 3.791

2.  Plasma 17OH-progesterone concentrations in newborn infants.

Authors:  I A Hughes; D Riad-Fahmy; K Griffiths
Journal:  Arch Dis Child       Date:  1979-05       Impact factor: 3.791

3.  Congenital adrenal hyperplasia--a clinical and genetic survey. Are we detecting male salt-losers?

Authors:  L Murtaza; J R Sibert; I Hughes; I C Balfour
Journal:  Arch Dis Child       Date:  1980-08       Impact factor: 3.791

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.